Conjugates of glycosylated/galactosylated peptide,...

Details Conjugates of glycosylated/galactosylated peptide,... Conjugates of glycosylated/galactosylated peptide,...

2007-08-28

2007-08-28

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S002600, C514S008100, C514S049000, C530S391900, C530S391700, C530S395000, C530S397000, C530S322000, C536S023100

Reexamination Certificate

active

11152135

ABSTRACT:
A conjugate of formula A-L-P, in which:A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor,L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific manner, andP represents a monomer, homopolymer or heteropolymer comprising at least one nucleotide or an analogue thereof, which inhibits the intracellular biosynthesis of nucleotides or nucleic acids in a sequence-independent manner,wherein either or both of the covalent bond between A and L and the covalent bond between L and P can be cleaved intracellularly; a composition comprising such a conjugate; and a method of inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal.

REFERENCES:
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4680338 (1987-07-01), Sundoro
patent: 4725677 (1988-02-01), Köster et al.
patent: 4770183 (1988-09-01), Groman et al.
patent: 4827945 (1989-05-01), Groman et al.
patent: 4952394 (1990-08-01), Senter
patent: 4975278 (1990-12-01), Senter et al.
patent: 5006652 (1991-04-01), Cullinan et al.
patent: 5010176 (1991-04-01), Barton
patent: 5017693 (1991-05-01), Hylarides et al.
patent: 5028697 (1991-07-01), Johnson et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5094849 (1992-03-01), Cullinan et al.
patent: 5116944 (1992-05-01), Sivam et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5141648 (1992-08-01), Hylarides et al.
patent: 5141739 (1992-08-01), Jung et al.
patent: 5144012 (1992-09-01), Johnson et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5248492 (1993-09-01), Groman et al.
patent: 5280113 (1994-01-01), Rademacher et al.
patent: 5284646 (1994-02-01), Menz et al.
patent: 5308604 (1994-05-01), Sinn et al.
patent: 5336506 (1994-08-01), Josephson et al.
patent: 5342607 (1994-08-01), Josephson
patent: 5352432 (1994-10-01), Menz et al.
patent: 5393737 (1995-02-01), Mayers et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5478576 (1995-12-01), Jung et al.
patent: 5490991 (1996-02-01), Enriquez et al.
patent: 5492821 (1996-02-01), Callstrom et al.
patent: 5495006 (1996-02-01), Climie et al.
patent: 5554386 (1996-09-01), Groman et al.
patent: 5563250 (1996-10-01), Hylarides et al.
patent: 5574142 (1996-11-01), Meyer, Jr. et al.
patent: 5589334 (1996-12-01), Coulie et al.
patent: 5612474 (1997-03-01), Patel
patent: 5614505 (1997-03-01), Gmeiner et al.
patent: 5622929 (1997-04-01), Willner et al.
patent: 5635382 (1997-06-01), Low et al.
patent: 5639633 (1997-06-01), Callstrom et al.
patent: 5646298 (1997-07-01), Powell
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5665358 (1997-09-01), Barton et al.
patent: 5679323 (1997-10-01), Menz et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5700921 (1997-12-01), Westling et al.
patent: 5700922 (1997-12-01), Cook
patent: 5741900 (1998-04-01), Gmeiner et al.
patent: 5773435 (1998-06-01), Kadow et al.
patent: 5789248 (1998-08-01), Fodstad et al.
patent: 5840674 (1998-11-01), Yatvin et al.
patent: 5846728 (1998-12-01), Haralambidis et al.
patent: 5880097 (1999-03-01), Lyttle et al.
patent: 5880270 (1999-03-01), Berninger et al.
patent: 5929049 (1999-07-01), Singh et al.
patent: 5981507 (1999-11-01), Josephson et al.
patent: 5994517 (1999-11-01), Ts'o et al.
patent: 6005094 (1999-12-01), Simon et al.
patent: 6005098 (1999-12-01), Hattori et al.
patent: 6030997 (2000-02-01), Eliat et al.
patent: 6037329 (2000-03-01), Baird et al.
patent: 6063604 (2000-05-01), Wick et al.
patent: 6077837 (2000-06-01), Kozak
patent: 6114520 (2000-09-01), Hattori et al.
patent: 6187335 (2001-02-01), Brey et al.
patent: 6342485 (2002-01-01), Gmeiner et al.
patent: 0 884 327 (2001-03-01), None
patent: 97/20563 (1997-06-01), None
patent: 00/69473 (2000-11-01), None
patent: 01/32623 (2001-05-01), None
Agrawal et al., “Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus,”Proc. Natl. Acad. Sci. USA, 85(19):7079-7083 (1988) Abstract Only.
Agris et al., “Inhibition of Vesicular Stomatitis Virus Protein Synthesis and Infection by Sequence-Specific Oligodeoxyribonucleoside Methylphosphonates,”Biochemistry, 25:6268-6275 (1986).
Akhtar et al., “Stability of Antisense DNA Oligodeoxynucleotide Analogs in Cellular Extracts and Sera,”Life Science, 49: 1793-1801, (1991).
Alt et al., “Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation,”Arch. Virol, 142:589-599 (1997).
Andersson, “Reduction and Reoxidation of the Disulfide Bonds of Bovine Serum Albumin,”Archives of Biochemistry and Biophysics, 133:277-285 (1969).
Asayama et al., “Synthesis Of Novel Polyampholyte Comb-Type Copolymers Consisting Of A Poly (L-Lysine) Backbone And Hyaluronic Acid Side Changes For A DNA Carrier,”Bioconjugate Chem., 9: 476-481 (1998).
Bider et al., “Ligand-induced Endocytosis of the Asialoglycoprotein Receptor: Evidence for Heterogeneity in Subunit Oligomerization,”FEBS Lett. 434; 37-41 (1998).
Biessen et al., “Cholesterol Derivative of a New Triantenarry Cluster Galactoside Directs Low- and High-density Lipoproteins to the Parenchymal Liver Cell,”Biochem. J., 302: 283-289 (1994).
Biessen et al., “Synthesis of Cluster Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor,”J. Med. Chem., 38: 1538-1546 (1995).
Biessen et al., “Cholesterol Derivative of a New Triantenarry Cluster Galactoside Lowers Serum Cholesterol Levels and Enhances Secretion of Bile Acids in the Rat,”Circulation, 91: 1847-1854 (1995).
Biessen et al., “Targeted Delivery of Oligonucleotides to Parenchymal Liver Cells in Vivo,”Biochem. J., 340: 783-792 (1999).
Biessen et al., “Targeted Delivery of Antisense Oligonucleotides to Parenchymal Liver Cells in Vivo,”Methods in Enzymology, 314: 324-342 (1999).
Biessen et al., “Novel Hepatotrophic Prodrugs of the Antiviral Nucleoside 9-(2-Phosphonylmethoxyethyl) Adenine with Improved Pharmacokinetics and Antiviral Activity,”FASEB J., 14: 1784-1792 (Sep. 2000).
Bonfils et al., “Drug targeting: Synthesis and Endocytosis of Oligonucleotide-Neoglycoprotein Conjugates,”Nucleic Acids Res., 20(17): 4621-4629 (1992).
Boussif et al., “A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in Vivo: Polyethylenimine,”Proc. Natl. Acad. Sci. USA, 92: 7297-7301 (1995).
Breton et al., “Production of Macrophage-derived Cytotoxic Factor byN-[3-[(Carbamoylmethyl)thio]propionylated] Neoglycoproteins,”Bioconjugate Chemistry, 2: 16-18 (1991).
Bruix, “Treatment of Hepatocellular Carcinoma,”Hepatology, 25: 259-262 (1997).
Bunnell et al., “Targeted Delivery of Antisense Oligonucleotides by Molecular Conjugates,”Somatic Cell and Molecular Genetics, 18(6): 559-569 (1992).
Caruthers, “Chemical Synthesis of DNA and DNA Analogues,”Acc. Chem. Res. 24: 278-284 (1991).
Cattaneo-Pangrazzi et al., “Cell-cycle Arrest and p53-independent Induction of Apoptosis in Vitro by the New Anticancer Drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 Human Prostate Cancer Cells,”J. Cancer Res. Clin. Oncol., 126: 247-256 (May 2000).
Cheng et al., “Characterization of an Antineoplastic Glucuronide Prodrug,”Biochem. Pharmacol., 58: 325-328 (1999).
Chipowsky et al., “Synthesis of 1-thioaldosides Having an Amino Group at the Aclycon Terminal,”Carbohydrate Res., 31: 339-346 (1973).
Chu et al., “Presentation of Ligands on Hydroxylapatite,”Bioconjugate Chem., 8: 103-105 (1997).
Czerwinski et al., “Cytotoxic Agents Directed to Peptide Hormone Receptors: Defining the Requirements for a Succ

Affiliated with

Also associated with

Rating

Conjugates of glycosylated/galactosylated peptide,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conjugates of glycosylated/galactosylated peptide,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of glycosylated/galactosylated peptide,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3882815